# Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma

> **NCT06871007** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **St. Petersburg State Pavlov Medical University** · enrollment: 22 (estimated)

## Conditions studied

- Primary Mediastinal (Thymic) Large B-cell Lymphoma
- Children
- Nivolumab

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT06871007
- **Lead sponsor:** St. Petersburg State Pavlov Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-09-01
- **Primary completion:** 2029-09-01
- **Final completion:** 2031-09-01
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06871007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06871007, "Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06871007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*